Skip to main content
. 2018 Jan 8;9(6):6924–6937. doi: 10.18632/oncotarget.24023

Figure 6. Nude mice bearing MCF-7 breast cancer xenograft were treated with either fulvestrant by s.c. injection or ZB716 at two different doses PO.

Figure 6

Treatment continued for three weeks before the animals were sacrificed and plasma and tumor tissues were collected. (A) tumor volumes were plotted vs. days of drug treatment; (B) concentration of ZB716 and fulvestrant in final plasma and tumor tissue samples at end of study; (C) WES analysis of ER expression in tumors collected at end of study; and (D) average ER expression in tumor tissues at end of study.